Sickle Cell Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

 Breaking News
  • No posts were found

Sickle Cell Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

September 22
23:57 2023
Sickle Cell Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

DelveInsight’s, “Sickle Cell Disease Pipeline Insights 2023” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Sickle cell disease pipeline landscape. It covers the Sickle Cell Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sickle Cell Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Sickle Cell Disease Pipeline Report

  • DelveInsight’s Sickle Cell Disease pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Sickle Cell Disease treatment.
  • The leading companies working in the Sickle Cell Disease Market include Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others.
  • Promising Sickle Cell Disease Pipeline Therapies in the various stages of development include SHP655, Prasugrel, FT-4202, Crizanlizumab, Sevuparin, Voxelotor, NKTT120, Aes-103, CTX001, and others.
  • August 2023: Pfizer announced a study of phase 3 clinical trials for Voxelotor. This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) measurements in SCD participants in this age range.
  • August 2023: Vifor Pharma Inc. announced a study of phase 2 clinical trials for VIT-2763 120 mg. The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD). The safety, tolerability and clinical beneficial effects of VIT-2763 for the treatment of SCD are also explored.

 

Request a sample and discover the recent advances in Sickle Cell Disease Treatment Drugs @ Sickle Cell Disease Pipeline Report

 

In the Sickle Cell Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sickle Cell Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Sickle Cell Disease Overview

Sickle cell disease is the name given for a group of inherited conditions that affect the red blood cells and the most serious type is called Sickle cell anemia. Sickle cells are destroyed rapidly in the bodies of people with the disease, causing anemia which is why it is commonly known as sickle cell anemia.

 

Find out more about Sickle Cell Disease Treatment Drugs @ Drugs for Sickle Cell Disease Treatment

 

Sickle Cell Disease Emerging Drugs Profile

  • BPX-501 T cells: Bellicum Pharmaceuticals
  • Canakinumab: Novartis
  • EPI01: Novo Nordisk
  • CTX001: Vertex Pharmaceuticals

 

Sickle Cell Disease Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Sickle Cell Disease therapies. The Sickle Cell Disease companies which have their Sickle Cell Disease (SCD) drug candidates in the most advanced stage, i.e. Phase III include Vertex Pharmaceuticals.

 

Learn more about the emerging Sickle Cell Disease Pipeline Therapies @ Sickle Cell Disease Clinical Trials Assessment

 

Scope of the Sickle Cell Disease Pipeline Report

  • Coverage- Global
  • Sickle Cell Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Sickle Cell Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Sickle Cell Disease Companies- Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others.
  • Sickle Cell Disease Pipeline Therapies- SHP655, Prasugrel, FT-4202, Crizanlizumab, Sevuparin, Voxelotor, NKTT120, Aes-103, CTX001, and others.

 

Dive deep into rich insights for new drugs for Sickle Cell Disease treatment, Visit @ Sickle Cell Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Sickle Cell Disease (SCD): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Sickle Cell Disease (SCD)– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase III)
  8. CTX001: Vertex Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II/III)
  11. Mitapivat: Agios Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ARU-1801: Aruvant Sciences
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. GBT021601: Global Blood Therapeutics, Inc.
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. TALGlobin01: Cellectis
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Sickle Cell Disease Key Companies
  24. Sickle Cell Disease Key Products
  25. Sickle Cell Disease Unmet Needs
  26. Sickle Cell Disease Market Drivers and Barriers
  27. Sickle Cell Disease Future Perspectives and Conclusion
  28. Sickle Cell Disease Analyst Views
  29. Sickle Cell Disease Key Companies
  30. Appendix

 

For further information on the Sickle Cell Disease pipeline therapeutics, reach out to Sickle Cell Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Related Articles

Calendar

December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031

Categories